These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11454541)

  • 1. High, intermittent dose of all-trans retinoic acid in combination with alpha-interferon for advanced multiple myeloma.
    Juturi J; Bukowski RA; Bocock K; Bloom T; Finke J; Hussein MA
    Haematologica; 2001 Jul; 86(7):776-7. PubMed ID: 11454541
    [No Abstract]   [Full Text] [Related]  

  • 2. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.
    Musto P; Sajeva MR; Sanpaolo G; D'Arena G; Scalzulli PR; Carotenuto M
    Haematologica; 1997; 82(3):354-6. PubMed ID: 9234591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyomatous differentiation in primary Wilms tumor and hepatic metastases after chemotherapy and all-trans-retinoic acid in combination with interferon-α.
    Chao YH; Wu HP; Chiang IP; Peng CT; Yang YL; Wu KH
    Pediatr Blood Cancer; 2011 Oct; 57(4):698-9. PubMed ID: 21648057
    [No Abstract]   [Full Text] [Related]  

  • 4. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination of interferon-alpha and all-trans-retinoic acid as a treatment for maintaining remission in high-risk group patients with acute myeloid leukemia].
    Parovichnikova EN; Savchenko VG; Isaev VG; Demidova IA; Ol'shanskaia IuV; Lapin VA; Cherepanova VV; Rekhtman GB; Perekatova TN
    Ter Arkh; 2001; 73(7):15-20. PubMed ID: 11523403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
    Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
    Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
    Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial.
    Koskela K; Pelliniemi TT; Pulkki K; Remes K
    Leuk Lymphoma; 2004 Apr; 45(4):749-54. PubMed ID: 15160951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
    Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E
    J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.
    Kraut EH; Young D; Farag S; James AG; Solove RJ
    Leuk Res; 2005 Oct; 29(10):1233-4. PubMed ID: 16111541
    [No Abstract]   [Full Text] [Related]  

  • 11. [Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group].
    Krejcí M; Hájek R; Scudla V; Bacovský J; Indrák K; Faber E; Koza V; Schützová M; Kuca B; Sumná E; Franková H; Lehanka F; Gumulec J; Stavarová Y; Rezek Z; Praskac P; Cahová S; Vránová M; Veprek K; Januska J; Kessler P; Pozdĕnová V; Walterová L; Stefánek I; Hausdorf P; Meluzínová I; Novosadová L; Lenícková S; Dusek L; Syobodník A; Králová E; Adam Z; Mayer J; Vorlícek J
    Vnitr Lek; 2001 Sep; 47 Suppl 1():40-7. PubMed ID: 11693062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.
    van der Spek E; Bloem AC; van de Donk NW; Bogers LH; van der Griend R; Kramer MH; de Weerdt O; Wittebol S; Lokhorst HM
    Haematologica; 2006 Apr; 91(4):542-5. PubMed ID: 16585018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
    J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
    Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
    Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on thalidomide usage in myeloma.
    Myers B
    Haematologica; 2002 Jun; 87(6):ELT29. PubMed ID: 12031937
    [No Abstract]   [Full Text] [Related]  

  • 16. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E; Bloem AC; Sinnige HA; Lokhorst HM
    Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of all-trans-retinoic acid administered on intermittent schedule by alpha-interferon 2a in a patient with AIDS-related Kaposi's sarcoma.
    Toma S; Iacona I; Palumbo R; Moresco L; Raffo P; Regazzi MB
    AIDS; 1996 Aug; 10(9):1049-50. PubMed ID: 8853745
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
    Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
    Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma.
    Yamamoto S; Tomita Y; Hoshida Y; Iizuka N; Marubashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Nakamori S; Sakon M; Aozasa K; Monden M
    J Gastroenterol; 2004 Aug; 39(8):793-7. PubMed ID: 15338375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.